The goal of this clinical trial is to evaluate whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.

The main questions it aims to answer are:

• Does Nuvastatic 300 mg capsules significantly reduce cancer-related fatigue compared to placebo?
• Is Nuvastatic 300 mg capsules safe and well tolerated in this patient population?

Researchers will compare Nuvastatic 300 mg capsules vs placebo to see if Nuvastatic 300 capsule improves fatigue scores and maintains an acceptable safety profile.

Participants will:

• Receive Nuvastatic 300 mg capsules or placebo capsules (3 times per day) for 3 cycles of 20 days each (total ~60 treatment days).
• Continue their standard first-line chemotherapy regimen.
• Provide blood sample assessments at Screening and End of Treatment.
• Complete patient diaries and fatigue assessments as per protocol.